본문 바로가기
KERD
논문KCI 등재

우울증에서 에스케타민의 임상 적용: 서술적 문헌 고찰

Clinical Application of Esketamine in Depression: A Narrative Review

이화영|최범성
대한생물정신의학회 (The Korean Society Of Biological Psychiatry)|2024.10|생물정신의학 (Journal of Korean Society of Biological Psychiatry)|제31권 제2호|pp. 15-19|DOI 10.22857/kjbp.2024.31.2.001

2

조회

0

다운로드

0

인용

0

참고문헌

키워드

Major depressive disorderEsketamineSuicide.Treatment-resistant depression
주제분류정신과학

초록

Mood disorders are a major cause of morbidity. Many patients experience treatment-resistant depression, and suicide rates are on the rise. There is a critical need for faster-acting and more effective antidepressants. After decades of research, esketamine, initially used as an anesthetic, has begun to be used as an outpatient treatment for major depressive disorder. Esketamine, an N-methyl-D-aspartate receptor antagonist, directly targets the glutamate system, rapidly improving mood symptoms and reducing suicidal ideation. Esketamine has demonstrated superior efficacy in reducing depressive symptoms more quickly than traditional oral antidepressant monotherapy, with a favorable risk-benefit profile. Reported side effects include sedation, dizziness, dissociative reactions, and increased blood pressure, though these effects are generally limited to the monitoring period of approximately two hours following administration.

Abstract

Mood disorders are a major cause of morbidity. Many patients experience treatment-resistant depression, and suicide rates are on the rise. There is a critical need for faster-acting and more effective antidepressants. After decades of research, esketamine, initially used as an anesthetic, has begun to be used as an outpatient treatment for major depressive disorder. Esketamine, an N-methyl-D-aspartate receptor antagonist, directly targets the glutamate system, rapidly improving mood symptoms and reducing suicidal ideation. Esketamine has demonstrated superior efficacy in reducing depressive symptoms more quickly than traditional oral antidepressant monotherapy, with a favorable risk-benefit profile. Reported side effects include sedation, dizziness, dissociative reactions, and increased blood pressure, though these effects are generally limited to the monitoring period of approximately two hours following administration.

참고문헌 (42)

  1. Akil H, "Treatment resistant depression : a multi-scale, systems biology approach", Neurosci Biobehav Rev, 84, pp.272~288 (2018)
  2. Ferrari AJ, "Burden of depressive disorders by country, sex, age, and year : findings from the global burden of disease study 2010", PLoS Med, 10, pp.e1001547~ (2013)
  3. Rush AJ, "Sequenced treatment alternatives to relieve depression(STAR*D) : rationale and design", Control Clin Trials, 25, pp.119~142 (2004)
  4. Bennabi D, "Risk factors for treatment resistance in unipolar depression : a systematic review", J Affect Disord, 171, pp.137~141 (2015)
  5. Curtin SC, "Increase in suicide in the United States, 1999-2014", NCHS Data Brief, 241, pp.1~8 (2016)
  6. "FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic"[URL]
  7. "SPRAVATO® (esketamine)prescribing information" (2020)[URL]
  8. Henter ID, "Glutamatergic modulators in depression", Harv Rev Psychiatry, 26, pp.307~319 (2018)
  9. Lapidus KA, "A randomized controlled trial of intranasal ketamine in major depressive disorder", Biol Psychiatry, 76, pp.970~976 (2014)
  10. Shen Z, "A meta-analysis of the effects of ketamine on suicidal ideation in depression patients", Transl Psychiatry, 14, pp.248~ (2024)
  11. "Integrated pharmaceutical information system. Spravato nasal spray (esketamine hydrochloride)" (2020)[URL]
  12. Ritter P, "Ketamine in the treatment of depressive episodes", Pharmacopsychiatry, 53, pp.45~50 (2020)
  13. Fedgchin M, "Efficacy and safety of fixed-dose esketamine nasal spray combined with a new oral antidepressant in treatment-resistant depression : results of a randomized, double-blind, active-controlled study(TRANSFORM-1)", Int J Neuropsychopharmacol, 22, pp.616~630 (2019)
  14. Popova V, "Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression : a randomized double-blind active-controlled study", Am J Psychiatry, 176, pp.428~438 (2019)
  15. Muller J, "Ketamine enantiomers in the rapid and sustained antidepressant effects", Ther Adv Psychopharmacol, 6, pp.185~192 (2016)
  16. Yanagihara Y, "Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers", Biopharm Drug Dispos, 24, pp.37~43 (2003)
  17. Patel S, "Spravato for treatment-resistant depression", Drug Topics, 163, pp.40~41 (2019)
  18. Peltoniemi MA, "Ketamine : a review of clinical pharmacokinetics and pharmacodynamics in anesthesia and pain therapy", Clin Pharmacokinet, 55, pp.1059~1077 (2016)
  19. Mathew SJ, "Ketamine for treatment-resistant unipolar depression : current evidence", CNS Drugs, 26, pp.189~204 (2012)
  20. Mathews DC, "Current status of ketamine and related compounds for depression", J Clin Psychiatry, 74, pp.516~517 (2013)
  21. Bahr R, "Intranasal esketamine(SpravatoTM)for use in treatment-resistant depression in conjunction with an oral antidepressant", P T, 44, pp.340~375 (2019)
  22. Khorassani F, "Intranasal esketamine : a novel drug for treatment-resistant depression", Am J Health Syst Pharm, 77, pp.1382~1388 (2020)
  23. Perez-Ruixo C, "Population pharmacokinetics of esketamine nasal spray and its metabolite noresketamine in healthy subjects and patients with treatment-resistant depression", Clin Pharmacokinet, 60, pp.501~516 (2021)
  24. Correia-Melo FS, "Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression : a randomized, double-blind, non-inferiority study", J Affect Disord, 264, pp.527~534 (2020)
  25. Vickers BA, "A case report : subanesthetic ketamine infusion for treatment of cancer-related pain produces urinary urge incontinence", A A Case Rep, 8, pp.219~221 (2017)
  26. Schatzberg AF, "A word to the wise about intranasal esketamine", Am J Psychiatry, 176, pp.422~424 (2019)
  27. Gastaldon C, "Postmarketing safety concerns with esketamine : a disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system", Psychother Psychosom, 90, pp.41~48 (2020)
  28. Olofsen E, "The dose-dependent effect of S(+)-ketamine on cardiac output in healthy volunteers and complex regional pain syndrome type 1 chronic pain patients", Anesth Analg, 115, pp.536~546 (2012)
  29. Morgan CJ, "Ketamine use : a review", Addiction, 107, pp.27~38 (2012)
  30. Chen CH, "Ketamine-snorting associated cystitis", J Formos Med Assoc, 110, pp.787~791 (2011)
  31. Kalsi SS, "The epidemiology and patterns of acute and chronic toxicity associated with recreational ketamine use", Emerg Health Threats J, 4, pp.7107~ (2011)
  32. Gupta A, "A systematic review of ketamine for the treatment of depression among older adults", Int Psychogeriatr, 33, pp.179~191 (2021)
  33. Hartvig P, "Central nervous system effects of subdissociative doses of(S)-ketamine are related to plasma and brain concentrations measured with positron emission tomography in healthy volunteers", Clin Pharmacol Ther, 58, pp.165~173 (1995)
  34. Kritzer MD, "Ketamine for treatment of mood disorders and suicidality : a narrative review of recent progress", Ann Clin Psychiatry, 34, pp.33~43 (2022)
  35. "FDA briefing document:Psychopharmacologic Drugs Advisory Committee (PDAC)and Drug Safety and Risk Management (DSaRM) Advisory Committee meeting"[URL]
  36. Daly EJ, "Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression : a randomized clinical trial", JAMA Psychiatry, 75, pp.139~148 (2018)
  37. Ochs-Ross R, "Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3", Am J Geriatr Psychiatry, 28, pp.121~141 (2020)
  38. Daly EJ, "Efficacy of esketamine nasal spray plus oral antidepressant treatment for relapse prevention in patients with treatment-resistant depression : a randomized clinical trial", JAMA Psychiatry, 76, pp.893~903 (2019)
  39. Ochs-Ross R, "Comparison of long-term efficacy and safety of esketamine nasal spray plus oral antidepressant in younger versus older patients with treatment-resistant depression : post-hoc analysis of SUSTAIN-2, a longterm open-label phase 3 safety and efficacy study", Am J Geriatr Psychiatry, 30, pp.541~556 (2022)
  40. Turkoz I, "Treatment response with esketamine nasal spray plus an oral antidepressant in patients with treatment-resistant depression without evidence of early response : a pooled post hoc analysis of the TRANSFORM studies", J Clin Psychiatry, 82, pp.20m13800~ (2021)
  41. Zhang XX, "Research advances in the clinical application of esketamine", Ibrain, 8, pp.55~67 (2022)
  42. Sanacora G, "A consensus statement on the use of ketamine in the treatment of mood disorders", JAMA Psychiatry, 74, pp.399~405 (2017)

관련 논문AI추천

케타민의 항우울 효과와 임상적 적용김병수대한생물치료정신의학회 · 생물치료정신의학2020 · 제26권 제2호Ketamine의 속효성 항우울효과와 임상 적용김용구, 신철민대한신경정신의학회 · 신경정신의학2018 · 제57권 제2호Ketamine in Major Depressive Disorder: Mechanisms and Future Perspectives김용구, 신민철대한신경정신의학회 · PSYCHIATRY INVESTIGATION2020 · 제17권 제3호Rapid Onset of Intranasal Esketamine in Patients with Treatment Resistant Depression and Major Depression with Suicide Ideation: A Meta-Analysis박원명, Chi-Un Pae, Hae-Ran Na, Hyun Kook Lim, Nak-Young Kim, Sheng Min Wang, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2021 · 제19권 제2호케타민의 빠른 항우울효과오대영대한생물정신의학회 · 생물정신의학2013 · 제20권 제2호Rapid-acting NMDA and GABAergic Modulators in Mood Disorders: From Synaptic Mechanisms to Clinical PracticeAlessandro Serretti대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2025 · 제23권 제4호

이 간행물의 다른 논문 (4건)

주요우울장애에서의 뇌연령 예측을 위한 자기공명영상 기반 머신러닝모델 연구의 고찰유서영, 윤수정, 주윤지pp. 20-33다약제 치료를 받는 조현병 환자에서 Aripiprazole Once-Monthly 투여의 임상적 부담정수봉, 조성준, 김준형, 김은수, 이상민, 신영철, 김원형, 양혜련, 장진구, 방민지, 전상원, 정슬아, 김장래, 문지완, 신동원, 오강섭, 김민경pp. 34-39응급실 내원 환자에서 자살시도와 말초 혈액 지표 간의 연관성김양식, 김원형, 배재남, 맹세리, 최석호, 최서현, 이정섭pp. 40-50스타틴 사용과 양극성 장애 발병의 연관성정진형, 전홍진, 신지원, 김혜원, 한경도pp. 51-58
원문 보기